Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Technology That’s Everywhere From Kindergarten Classes To Cardiac Research

Virtual reality and augmented reality are increasing in importance in business and even in everyday life. While many people think of VR and AR as a cool way to play video games—think of Pokemon Go as the flagship of AR gaming—both are in fact much more useful beyond gaming. Medicine is a field that is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Virtual reality and augmented reality are increasing in importance in business and even in everyday life. While many people think of VR and AR as a cool way to play video games—think of Pokemon Go as the flagship of AR gaming—both are in fact much more useful beyond gaming.

Medicine is a field that is already using VR technology to its advantage and is seeing results that can help save lives. Doctors are already using VR in the pre-planning phase of surgery to better visualize incisions and to go over strategy. There is little question that these kinds of medical VR uses will only expand precisely because exploratory surgeries can now be done virtually, and as a result, much more safely. If a doctor can see inside a patient in three dimensions before operating, then surgery is much more likely to be safe and successful.

Education is another place where VR and AR can be very useful. By creating a virtual environment in the classroom, students can immerse themselves in a subject. Instead of going on a field trip, a class can quickly be brought to a different part of the world, and even a different era entirely, because of virtual reality. It can also elevate the learning experience from the classic textbook experience by showing graphics and models in 3D.

Auto designers, architects, and interior designers are already using VR and AR, and it’s likely those industries are only going to expand their use. AR can be especially useful for interior designers, as they will be able to show customers in their actual space how furniture is going to look in a certain area or what it will look like with a new wall or other design elements. This development might eventually remove the need for renderings. Artist concepts will come ever closer to what the finished product will look like.

Of course, VR is still in its early stages as far its integration to the general public. Yet, there is little question its cost and practical uses are improving. As costs decrease and quality increases, more and more private uses of the technology will become available. Whether it is gaming, watching films, or virtual travel—and potentially improving quality of life for many people—VR is opening up possibilities the public has only just begun to imagine, virtually or otherwise.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512